OpportunityTitle: 2010 NIDA Translational Avant-Garde Award for Medication Development for Diseases of Addiction (DP1)
AdditionalInformationOnEligibility: Other Eligible Applicants include the following:  Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Description: Purpose The NIDA Translational Avant-Garde Award is designed to support dedicated and talented basic and/or clinical researchers with the vision, drive and expertise necessary to translate research discoveries into medications for the treatment of diseases of addiction. Through this funding FOA, the National Institute on Drug Abuse (NIDA) is committed to making significant advances in the development of safe and efficacious products for the treatment of disorders stemming from tobacco, cannabis, cocaine, methamphetamine, heroin, or prescription opiate use or abuse. These products can be pharmaceuticals (small molecules) or biologics. Biologics include medicinal products such as vaccines and recombinant therapeutic proteins created by biological processes. Applications may focus on the pharmacotherapy of one or various disorders. Applications may also focus on the specific symptoms of the disorder such as withdrawal, craving or relapse. Testing of new formulations of marketed medications that are available for other indications, or new combinations of existing medications, which may be promising candidates for the treatment of diseases of addiction is within the scope of this FOA. The 2010 Translational Avant-Garde Award competition will proceed in two phases. The first phase is a pre-application phase in response to PAR-10-095. Pre-applications will be evaluated by a group of external reviewers. Those investigators whose submissions are judged to be the most outstanding will be notified of the opportunity to submit full applications under this FOA (DP1). The 2010 Avant-Garde awardees will be selected from this group of applicants. Mechanism of Support. This FOA will utilize the DP1 grant mechanism. Pre-applications for 2010 Translational Avant-Garde Awards were encouraged under PAR-10-095. Funds Available and Anticipated Number of Awards. Contingent upon the submission of a sufficient number of scientifically meritorious applications, NIDA intends to commit $2 million for 2-3 awards in fiscal 2010.
GrantorContactEmailDescription: If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
GrantorContactText: NIH OER Webmaster&lt;br/&gt;FBOWebmaster@OD.NIH.GOV&lt;br/&gt;